A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder

• Status: Completed
• Trial end date: 2003-09-30
• Target enrollment: 0
• Participant gender: All

Summary

A Placebo Controlled Study Evaluating Efficacy And Safety of Medication In Patients With Major Depressive Disorder (MDD)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Paroxetine; Vestipitant

Criteria

Inclusion Criteria:

• Patients meet the diagnosis of Major Depressive Disorder (MDD).

Exclusion Criteria:

• Patients with a primary diagnosis other than MDD.

• Patients with a history of schizophrenia, schizoaffective disorders, seizure disorders or bipolar affective disorder.

• Patients receiving formal psychotherapy or cognitive/behavioral therapy concurrently or in the 12 weeks prior to screening visit.

• Patient is actively suicidal.

• Patients who have a history of migraine headaches.